Vantia Therapeutics’ lead candidate VA106483 demonstrates positive anti-diuretic effect in Phase IIa trial in nocturia
Advertisement
Vantia Therapeutics announced positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. The study also found that VA106483 was generally well tolerated among the patient population.
VA106483 is a novel small molecule drug candidate that exerts its effect directly in the kidney by binding to vasopressin (V2) receptors, which regulate water balance. It was discovered by Vantia from its drug candidate library.
The double-blind, placebo-controlled, dose-response study was designed to investigate the pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483. The trial involved 27 elderly men aged 65 years or more with a history of nocturia.
Based on these results, Vantia now plans to advance VA106483 into a larger Phase IIb clinical efficacy study in the second half of 2009.
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
List_of_diseases_(W)
P4_medicine
Hexvix guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer
Creation of a detailed "catalogue" of degradation products in cells - New insights into a quality control mechanism that removes defective genetic products from cells
Bovine_spongiform_encephalopathy
How to achieve and maintain pharmaceutical compliance - Pharmaceutical Compliance Guide
PerkinElmer announces third quarter results - GAAP Revenue of $548 million versus $563 million in the comparable prior period
Category:Cardiac_surgery
Sigma-Aldrich and Sangamo BioSciences Announce Alliance to Develop Zinc Finger-Based Laboratory Research Reagents